JPMorgan cuts Yuhan stock rating to Underweight, sets KRW80,000 PT

Published 22/05/2025, 06:18
JPMorgan cuts Yuhan stock rating to Underweight, sets KRW80,000 PT

On Thursday, JPMorgan initiated coverage on Yuhan Corp (000100:KS) with an Underweight rating and set a price target of KRW 80,000. The new rating reflects the investment bank’s view on the South Korean pharmaceutical company’s future earnings potential.

Yuhan has experienced a surge in its stock value, which climbed 137% in fiscal year 2024 to its peak in October, outperforming a flat index. This was primarily due to increasing royalty income from lazertinib, which is used in a combination therapy for non-small cell lung cancer (NSCLC) by Johnson & Johnson (NYSE:JNJ). The royalty income has been a significant factor in boosting Yuhan’s earnings outlook, which was previously based on a steady but low earnings base from its existing business.

Despite the positive performance, JPMorgan raised concerns that the market’s expectations for Yuhan may be overly optimistic. The bank pointed out that the smaller royalty income relative to global combination therapy sales, the sharing of royalty streams, and the increasing research and development costs could limit the upside in earnings. JPMorgan’s forecasts for Yuhan’s earnings show more than a doubling from fiscal year 2024 to 2027, which is less aggressive than the Bloomberg consensus that projects a threefold increase.

At a 70 times price-to-earnings ratio estimated for fiscal year 2026, JPMorgan suggests that the risk of further earnings misses could extend the stock’s current underperformance. The firm’s earnings estimates for fiscal years 2025 to 2027 are 20-40% below the consensus.

JPMorgan indicated that a recalibration of market expectations for Yuhan in the upcoming quarters could potentially shift their stance to a more positive outlook on what they recognize as a fundamentally sound business.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.